Technical Analysis for AGIO - Agios Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
C 29.29 -2.17% -0.65
AGIO closed down 2.17 percent on Monday, March 18, 2024, on 76 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Oversold Stochastic Weakness 0.00%
Bullish Engulfing Bullish -2.17%
Pocket Pivot Bullish Swing Setup -2.17%
Multiple of Ten Bearish Other -2.17%
Oversold Stochastic Weakness -2.17%
Stochastic Reached Oversold Weakness -0.58%
Wide Bands Range Expansion -0.58%
Down 3 Days in a Row Weakness -0.58%
Down 4 Days in a Row Weakness -0.58%
Down 5 Days in a Row Weakness -0.58%

   Recent Intraday Alerts

Alert Time
Down 3% about 21 hours ago
Fell Below Previous Day's Low about 21 hours ago
Down 2 % about 21 hours ago
Down 1% about 22 hours ago
60 Minute Opening Range Breakout 4 days ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Agios Pharmaceuticals, Inc. Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its products include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations; and enzyme glutaminase that converts the nutrient glutamine into the metabolite glutamate. The company's products also comprise AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation. The company was founded in 2007 and is based in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Acid Hydrogen Metabolism Organic Chemistry Glutamate Inborn Errors Of Metabolism Pyruvate Kinase Deficiency

Is AGIO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 35.5
52 Week Low 19.795
Average Volume 858,026
200-Day Moving Average 25.18
50-Day Moving Average 26.51
20-Day Moving Average 31.02
10-Day Moving Average 30.56
Average True Range 1.28
RSI (14) 49.75
ADX 41.07
+DI 24.72
-DI 19.62
Chandelier Exit (Long, 3 ATRs) 31.66
Chandelier Exit (Short, 3 ATRs) 28.72
Upper Bollinger Bands 34.95
Lower Bollinger Band 27.09
Percent B (%b) 0.28
BandWidth 25.32
MACD Line 0.90
MACD Signal Line 1.48
MACD Histogram -0.5718
Fundamentals Value
Market Cap 1.64 Billion
Num Shares 55.9 Million
EPS -3.94
Price-to-Earnings (P/E) Ratio -7.43
Price-to-Sales 58.47
Price-to-Book 1.58
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 30.88
Resistance 3 (R3) 30.94 30.47 30.62
Resistance 2 (R2) 30.47 30.07 30.44 30.53
Resistance 1 (R1) 29.88 29.81 29.65 29.82 30.44
Pivot Point 29.41 29.41 29.29 29.38 29.41
Support 1 (S1) 28.82 29.01 28.59 28.76 28.14
Support 2 (S2) 28.35 28.75 28.32 28.05
Support 3 (S3) 27.76 28.35 27.97
Support 4 (S4) 27.70